FDA withdraws accelerated approval of myeloma drug
The Food and Drug Administration Feb. 23 withdrew approval of Pepaxto (melphalan flufenamide), a drug once used with dexamethasone to treat certain U.S. patients with multiple myeloma, because a post-approval trial did not show it safe or effective. This is the first time the agency has used procedures amended under the Food and Drug Omnibus Report Act of 2022 to withdraw accelerated approval of a drug. The drug is not currently marketed in the U.S., FDA said.
Related News Articles
Headline
The Food and Drug Administration April 29 announced results from its testing of more than 300 infant formulas, finding that the majority of samples had…
Headline
March 8-14 marks Patient Safety Awareness Week. The AHA has several resources including podcasts, videos and reports that show how AHA members are advancing…
Headline
A JAMA article co-authored by AHA Chief Physician Executive Chris DeRienzo, M.D., and leaders from Vizient highlights that hospitals and health systems have…
Headline
Kelley Sava, associate vice president of simulation at Advocate Health, and Brian Bjoern, M.D., patient safety manager at Laerdal Medical, share how simulation…
Headline
To help hospitals across the country improve sepsis care, the Centers for Disease Control and Prevention created the Hospital Sepsis Program Core Elements,…
Headline
The Food and Drug Administration today issued an alert on a potentially high-risk issue with Calyxo CVAC Aspiration Systems. In patients who have thick fluid…